Status: Not yet recruiting
rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia
This study aims to compare the efficacy and safety of recombinant human thrombopoietin (rhTPO) + cyclosporine (CsA) and CsA monotherapy in the treatment of lower-risk myelodysplastic neoplasms with thrombocytopenia.
Participants needed: 78
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Peking Union Medical College HospitalUpdated: Jun 17, 2026
Eligibility criteria
Age ≥ 18 years old; [+5]
History of leukemia or stem cell transplantation, treatment-related MDS or malig... [+8]